Viatris Inc. vs Dynavax Technologies Corporation: Examining Key Revenue Metrics

Viatris vs Dynavax: A Decade of Revenue Dynamics

__timestamp	Dynavax Technologies Corporation	Viatris Inc.
Wednesday, January 1, 2014	11032000	7719600000
Thursday, January 1, 2015	4050000	9429300000
Friday, January 1, 2016	11043000	11076900000
Sunday, January 1, 2017	327000	11907700000
Monday, January 1, 2018	8198000	11433900000
Tuesday, January 1, 2019	35219000	11500500000
Wednesday, January 1, 2020	46551000	11946000000
Friday, January 1, 2021	439442000	17886300000
Saturday, January 1, 2022	722683000	16262700000
Sunday, January 1, 2023	232284000	15426900000

Unveiling the hidden dimensions of data

Viatris Inc. vs Dynavax Technologies: A Revenue Journey

In the ever-evolving pharmaceutical landscape, Viatris Inc. and Dynavax Technologies Corporation have carved distinct paths. Over the past decade, Viatris has consistently demonstrated robust revenue growth, peaking in 2021 with a 55% increase from 2014. Meanwhile, Dynavax, a smaller player, has shown remarkable agility, with a staggering 6,500% revenue surge from 2017 to 2022, driven by strategic innovations and market expansions.

Key Insights

Viatris Inc.: From 2014 to 2023, Viatris maintained a steady revenue stream, with a notable peak in 2021, reflecting its strong market presence.
Dynavax Technologies: Despite a modest start, Dynavax's revenue skyrocketed, particularly between 2020 and 2022, highlighting its dynamic growth strategy.

This comparison underscores the diverse strategies and market dynamics shaping the pharmaceutical industry today.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025